Skip to content
HowShorted

ARROWHEAD PHARMACEUTICALS, INC. short interest in 2021

In 2021, ARROWHEAD PHARMACEUTICALS, INC.'s disclosed short interest ran from 5.11% of shares outstanding on 15 Jan 2021 to 2.56% on 31 Dec 2021, a change of -2.55 percentage points. The year's high was 5.11% on 15 Jan 2021 and its low 2.56% on 31 Dec 2021, averaging 3.78% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.33 days on 15 Apr 2021. Full history: ARROWHEAD PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ARROWHEAD PHARMACEUTICALS, INC. in 2021

2021 in figures

Start of year
5.11% (15 Jan 2021)
End of year
2.56% (31 Dec 2021)
Change
-2.55 pp
High
5.11% (15 Jan 2021)
Low
2.56% (31 Dec 2021)
Average
3.78%
Highest days to cover
10.33 (15 Apr 2021)
SEC filings marked
8

Every report in 2021

ARROWHEAD PHARMACEUTICALS, INC. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20215.11%6.07
29 Jan 20214.85%7.91
12 Feb 20214.83%6.7210-Q filed, results (8-K)
26 Feb 20214.96%7.43
15 Mar 20214.94%5.91
31 Mar 20214.69%6.18
15 Apr 20214.62%10.33
30 Apr 20214.46%8.41
14 May 20214.62%7.0810-Q filed, results (8-K)
28 May 20214.63%8.73
15 Jun 20214.27%5.02
30 Jun 20213.54%4.09
15 Jul 20213.19%2.05
30 Jul 20213.34%5.61
13 Aug 20212.97%4.0010-Q filed, results (8-K)
31 Aug 20212.98%6.62
15 Sep 20212.79%7.24
30 Sep 20213.07%5.44
15 Oct 20212.78%5.83
29 Oct 20212.78%8.08
15 Nov 20212.90%4.43
30 Nov 20212.73%3.4410-K filed, results (8-K)
15 Dec 20213.02%4.86
31 Dec 20212.56%4.20

See also: ARROWHEAD PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.